raltegravir

Type: Keyphrase

Name: raltegravir

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification

Massanella, Marta PhD*; Esteve, Anna PhD†; Buzón, Maria J. PhD*; Llibre, Josep M. MD‡; Puertas, Maria C. PhD*; Gatell, Josep M. MD§; Domingo, Pere MD‖; Stevenson, Mario PhD¶; Clotet, Bonaventura MD*,‡; Martinez-Picado, Javier PhD*,#; Blanco, Julià PhD*; ... [Published JAIDS - May 14 2013]

Entities: raltegravir, Discontinuance, HAART

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Agency Reviews Patent Application Approval Request for "Raltegravir Salts and Crystalline Forms Thereof"

(NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- A patent application by the inventors KWOKAL, Ana (Zagreb, HR); Hedvati, Lilach (Doar Na Hefer, IL); Burstein, Revital (Ramat-Hasharon, IL); Yeori, Adi (Tel Aviv, IL); Moshkovits-Kaptsan, ... [Published NewsRX - May 03 2013]

Entities: raltegravir, Salts, Zagreb, Tel Aviv

First reported May 02 2013 - Updated May 02 2013 - 2 reports

Merck & Co Inc

Merck cuts outlook as Q1 sales fall

But new R&D chief highlights potential of company's near-term pipeline Merck & Co joined its peer Pfizer in cutting its financial guidance for 2013 after reporting lower-than-expected first quarter revenues.Sales fell 9 per cent to $10.7bn in the quarter, ... [Published PMLive - May 02 2013]

Entities: Merck & Co Inc, Roger Perlmutter, infliximab, Research & Development, SIMPONI

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

Postexposure Prophylaxis (PEP) After Blast Injuries

, is director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital in Boston.From a colleague came this query:Needless to say, the bombing victims are currently facing far greater challenges than exposure to blood-borne ... [Published The Body - Apr 26 2013]

Entities: prophylaxis, HIV/AIDS, Infectious Diseases, Bombing

First reported Apr 22 2013 - Updated Apr 23 2013 - 1 reports

Postexposure Prophylaxis (PEP) After Blast Injuries

From a colleague came this query:Needless to say, the bombing victims are currently facing far greater challenges than exposure to blood-borne pathogens. But it's a very reasonable query and, as it turns out, there's an existing guideline that addresses ... [Published The Body PRO - Apr 22 2013]

Entities: prophylaxis, Bombing, Zidovudine, Blood-Borne Pathogens, raltegravir

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Tenofovir

FDA Updates Atripla Label

The U.S. Food and Drug Administration (FDA) has made changes to the label for the single-pill HIV antiretroviral combination therapy Atripla (efavirenz/emtricitabine/tenofovir). Among those changes and additions are:An advisory against taking Atripla ... [Published POZ.com - Apr 23 2013]

Entities: Atripla, Emtricitabine, Tenofovir

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Emtricitabine

Changes to label for Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets

FDA recently approved changes to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes:Lists Stribild as one of the drugs that should not be coadministered with AtriplaAdds drug interaction information ... [Published AEGIS - Apr 19 2013]

Entities: Emtricitabine, Tenofovir, Atripla

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

Antiretroviral Therapy Update From the 48th ICAAC/46th IDSA Annual Meeting

Dr Boyle is the director of ViralEd LLC, Stockton, NJ, vice-chair of the International Center for Equal Healthcare Access, and medical editor of HIVandHepatitis.com. Dr Cohen is research director, Community Research Initiative of New England, Springfield, ... [Published The AIDS Reader - Apr 18 2013]

Entities: HIV/AIDS, RNA, raltegravir

First reported Apr 11 2013 - Updated Apr 12 2013 - 2 reports

ISENTRESS (Raltegravir) Tablet, Film Coated [REMEDYREPACK INC. ]

Updated Date: Apr 12, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Apr 12 2013]

Entities: Isentress, raltegravir

First reported Apr 09 2013 - Updated Apr 09 2013 - 1 reports

Skeletal Muscle Toxicity and Raltegravir

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.Myalgia and proximal myopathy are more prevalent among patients receiving raltegravir-based ART.Activate your free online account for full access ... [Published AIDS Clinical Care - Apr 09 2013]

Entities: raltegravir, Toxicity, Myalgia

First reported Mar 22 2013 - Updated Mar 22 2013 - 1 reports

Human medicines European Public Assessment Report (EPAR): Isentress, raltegravir, Revision: 18, Authorised

[Published Pending EC decisions and European Public Assess ... - Mar 22 2013]

Entities: Isentress, raltegravir

First reported Mar 08 2013 - Updated Mar 08 2013 - 1 reports

ViiV Healthcare presents phase III SAILING study data of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1

ViiV Healthcare, a global specialist HIV company established in November 2009 by GSK and Pfizer dedicated to delivering advances in treatment and care for people living with HIV, has announced 24-week data from the phase III SAILING (ING111762) study ... [Published PharmaBiz - Mar 08 2013]

Entities: Dolutegravir, raltegravir, ViiV Healthcare, Phase III

Quotes

"The genius of looking for 2-LTR circles is that infected cells can't survive the trip from the sanctuary site to the blood, and neither can the HIV, but the 2-LTR circles live as long as the cells that they are resident in, which is about 10-20 days" he said

Team develops mathematical model to measure hidden HIV [Published Medical Xpress - May 08 2013]

...patent expiries coupled with the impact of currency and other headwinds," said Kenneth C Frazier, chairman and chief executive officer, Merck. "During the quarter, we took focused actions to reach our EPS target while at the same time advancing Merck's pipeline in our laboratories and through strategic deals and partnerships. I remain confident in the future opportunities for our strong and diverse business and committed to delivering long-term value to our shareholders."

Merck Releases 1Q 2013 Financial Results [Published Individual.com - May 06 2013]

"I am doing a very detailed review of programmes, of process and people and already two weeks in, I can say there is some opportunities for acceleration and for productivity enhancement" he said. Meantime, however, Merck's R&D spend looks set to increase in 2013 over 2012

Merck cuts outlook as Q1 sales fall [Published PMLive - May 02 2013]

...Analysts are concerned, however, and Andrew Baum at Citibank issued a research note saying that "the weakness of Merck's quarter can only be regarded as a clarion call for management and investors"

Merck & Co sales slide, $15 billion share buyback unveiled [Published Pharma Times - May 02 2013]

More Content

sort by: Date \| Relevance
Dynamics of CD8 T-Cell Activation After Discont... [Published JAIDS - May 14 2013]
Team develops mathematical model to measure hid... [Published Medical Xpress - May 08 2013]
Global dolutegravir market: Latest market resea... [Published TransWorldNews - May 08 2013]
Global elvitegravir market: New market research... [Published TransWorldNews - May 08 2013]
UD-led team develops mathematical model to meas... [Published Noodls - May 08 2013]
Merck Releases 1Q 2013 Financial Results [Published Individual.com - May 06 2013]
Agency Reviews Patent Application Approval Requ... [Published NewsRX - May 03 2013]
Merck cuts outlook as Q1 sales fall [Published PMLive - May 02 2013]
Merck & Co sales slide, $15 billion share buyba... [Published Pharma Times - May 02 2013]
Patent Application Titled "Deuterated Hiv Attac... [Published Equities.com - May 01 2013]
FDA rejects two Gilead HIV drugs as standalone ... [Published Reuters India - Apr 29 2013]
UPDATE 1-FDA rejects two Gilead HIV drugs as st... [Published Reuters - Apr 29 2013]
Postexposure Prophylaxis (PEP) After Blast Inju... [Published The Body - Apr 26 2013]
Elvitegravir (HIV) - Forecast and Market Analys... [Published PredictWallStreet - Apr 23 2013]
FDA Updates Atripla Label [Published POZ.com - Apr 23 2013]
Postexposure Prophylaxis (PEP) After Blast Inju... [Published The Body PRO - Apr 22 2013]
New Market Study Published: Dolutegravir (HIV) ... [Published Live-PR.com - Apr 21 2013]
Changes to label for Atripla (efavirenz/emtrici... [Published AEGIS - Apr 19 2013]
Antiretroviral Therapy Update From the 48th ICA... [Published The AIDS Reader - Apr 18 2013]
Dolutegravir (HIV) - Forecast and Market Analys... [Published Individual.com - Apr 15 2013]
ISENTRESS (Raltegravir) Tablet, Film Coated [RE... [Published DailyMed Drug Label Updates for the last seven ... - Apr 12 2013]
Reports from GlaxoSmithKline Add New Data to Fi... [Published NewsRX - Apr 12 2013]
New Findings from B.L. Kirk and Co-Researchers ... [Published NewsRX - Apr 12 2013]
ISENTRESS (Raltegravir) Tablet, Film Coated [RE... [Published DailyMed Drug Label Updates for the last seven ... - Apr 11 2013]
Skeletal Muscle Toxicity and Raltegravir [Published AIDS Clinical Care - Apr 09 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Mar 22 2013]
ViiV Healthcare presents phase III SAILING stud... [Published PharmaBiz - Mar 08 2013]
Merck Announces Appointment of Roger M. Perlmut... [Published Yahoo! Finance - Mar 07 2013]